There are 2789 resources available
1087P - The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
Presenter: Bozena Cybulska-Stopa
Session: ePoster Display
1088P - Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD)
Presenter: Jose Luis Manzano
Session: ePoster Display
1089TiP - Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma
Presenter: Aurelio Boerlin
Session: ePoster Display
1026TiP - A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
Presenter: Mehmet Altan
Session: ePoster Display
1027TiP - A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer
Presenter: Erkut Borazanci
Session: ePoster Display
1028TiP - ARC-12: Phase I/Ib dose escalation and dose expansion study to evaluate the safety and tolerability of AB308 + zimberelimab (AB122) in advanced malignancies
Presenter: Justin Call
Session: ePoster Display
1030TiP - An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Wallace Akerley
Session: ePoster Display
Resources:
Abstract